Compounded tirzepatide, explained

What compounded tirzepatide is

Tirzepatide is a once-weekly injectable that activates two gut-hormone receptors, GLP-1 and GIP. Eli Lilly sells it as Zepbound (approved for weight management) and Mounjaro (approved for type 2 diabetes). Both are made in Lilly's factories, inspected by the FDA, and come in fixed-dose pens or vials.

A compounded version is made by a pharmacy. The FDA describes compounding as a practice in which a licensed pharmacist or physician "combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient." For tirzepatide that means the pharmacy buys the raw active ingredient, dissolves it to a chosen concentration, fills multi-dose vials, and ships them against a prescription written for a specific person.

Two kinds of pharmacy can do this. 503A pharmacies are state-licensed and compound for identified patients on individual prescriptions; their products are not made under the FDA's manufacturing rules. 503B outsourcing facilities register with the FDA, are inspected by it, and must follow current good manufacturing practice, but their drugs are still unapproved. Most telehealth providers use a 503A partner; a few use 503B facilities.

The FDA's own words: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." Source: FDA compounding Q&A

Compounded tirzepatide vs Zepbound and Mounjaro

The difference is not the molecule but everything around it: who makes it, who checks it, how it is dosed, and what it costs. People searching for the difference between compounded tirzepatide and Zepbound usually want the table below.

Compounded versions are legal only when a prescriber documents a change that makes a significant difference for that patient. A product that copies a Zepbound strength one-for-one is what the FDA calls "essentially a copy" and is not permitted now that the shortage is over.

What tirzepatide is compounded with

A compounded product contains the tirzepatide active ingredient plus a sterile diluent (typically bacteriostatic water), and sometimes an additive. Vitamin B12 (cyanocobalamin) is the most common addition, marketed as easing nausea; some pharmacies add glycine, niacinamide or other vitamins. In April 2026 the FDA said adding B12 to a product that otherwise matches an approved strength does not by itself make it a lawful "different" drug.

Two sourcing questions matter more than the additives. First, the form of the ingredient: approved products use tirzepatide base. The FDA has warned about semaglutide salt forms (sodium and acetate) that are "different active ingredients" with "no lawful basis" in compounding; ask a provider to confirm its tirzepatide is the base form. Second, the source of the raw ingredient: since September 2025 the FDA maintains a "Green List" of acceptable GLP-1 ingredient suppliers and detains imports from unlisted sources.

Concentration is the other variable. Brand pens deliver one fixed dose; compounded vials come in many concentrations (for example 10 mg/mL or 17 mg/mL), and the patient measures each dose in "units" on an insulin syringe. That is where most of the reported dosing errors come from.

Is compounded tirzepatide still legal in 2026?

It is legal in a narrow way, and the window has been closing since late 2024. Mass compounding of a drug is allowed while the FDA lists it as in shortage. The FDA declared the tirzepatide shortage resolved on 2 October 2024 and reaffirmed that on 19 December 2024 after a challenge from the compounding industry. Enforcement discretion for 503A pharmacies ended on 18 February 2025 and for 503B facilities on 19 March 2025.

Compounders sued. A federal court in Texas sided with the FDA in May 2025, and on 27 August 2026 the Fifth Circuit Court of Appeals affirmed that decision, so the shortage removal stands.

What remains is the patient-specific exception in section 503A of the federal drug law: a compounder may make what would otherwise be a copy of an approved drug if the prescriber determines that a change "made for an identified individual patient" will "produce a significant difference for that patient". The FDA has said it does not intend to act against a pharmacy that fills four or fewer such prescriptions a month for a given product. That is the basis on which telehealth providers still sell "personalized" tirzepatide: non-standard doses, added ingredients, or oral and sublingual forms.

Enforcement has tightened through 2026. The FDA sent warning letters to a first group of compounded-GLP-1 sellers in September 2025 and to 30 telehealth companies on 20 February 2026, citing claims that implied their products were the same as approved drugs and marketing that hid which pharmacy actually made them. On 30 April 2026 the agency proposed removing tirzepatide, semaglutide and liraglutide from the 503B bulks list altogether; no final decision had been published as of this article's date. Eli Lilly's false-advertising suits against telehealth compounders have had mixed results: cases against Mochi Health and Henry Meds are proceeding on the "personalized" claims, while the case against Willow was dismissed.

Practical reading: a provider selling compounded tirzepatide in 2026 should be able to say which pharmacy makes it, why your prescription is patient-specific, and should never describe the product as "the same as Zepbound".

Is compounded tirzepatide safe?

Tirzepatide itself carries the same risks in any form: the approved labels warn about thyroid C-cell tumors seen in animal studies, and list nausea, diarrhea, vomiting and constipation as the most common side effects. In the Zepbound trials nausea affected 25–29% of patients on tirzepatide versus 8% on placebo. Compounded products add risks that come from how they are made and used, not from the molecule.

As of 31 May 2026 the FDA had received more than 730 adverse-event reports associated with compounded tirzepatide (and 990 for compounded semaglutide). The agency notes the true number is probably higher because state-licensed pharmacies are not required to report adverse events to it.

The single most documented hazard is dosing error. The FDA has described patients who injected 5 to 20 times the intended dose after confusing units, milligrams and millilitres on multi-dose vials, and prescribers who wrote "25 units" when they meant 0.25 mg. Reported effects included severe vomiting, dehydration, fainting, acute pancreatitis and gallstones, some requiring hospital care. The other documented problems are unapproved salt forms, ingredients from unverified suppliers, and counterfeit products sold as "for research use only".

None of this means every compounded product is dangerous. It means the checks the FDA performs on Zepbound are not performed here, so the quality depends entirely on the pharmacy and the prescriber, and the safety of each injection depends on measuring it correctly.

This page is educational. Whether any tirzepatide product is appropriate for you is a decision for a licensed clinician who knows your history. See the FDA's current statement on unapproved GLP-1 drugs.

What compounded tirzepatide costs

Telehealth providers advertise compounded tirzepatide at headline prices of roughly $90 to $216 a month, almost always for the lowest starting dose and often on a prepaid multi-month term or on top of a separate membership fee of $39–$149 a month. Ongoing prices after the first months cluster at $279 to $349 a month where providers publish them. The all-in figure is what matters: a $133 medication price plus a $75 membership is $208.

For comparison, Eli Lilly sells Zepbound vials and KwikPens directly for $299 (2.5 mg), $399 (5 mg) and $449 (7.5–15 mg) a month when refilled within 45 days, and Mounjaro pens for $499 at every dose. At the higher maintenance doses the gap between compounded and brand-name has narrowed to well under $100 a month for many providers.

Every provider price on this site is captured with a date and a source link. The cheapest compounded tirzepatide table ranks the providers we track by their all-in monthly cost, and each provider profile shows the full plan table under "What it costs".

How to choose a provider that sells it

Four checks separate a licensed telehealth service from a reseller, and each provider profile on Rate GLP-1 answers them in its "Is it legit?" section:

• A clinician licensed in your state reviews your intake. No "instant approval" and no prescription without an actual evaluation.
• The compounding pharmacy is named. You should be able to look it up with your state board of pharmacy or, for a 503B facility, on the FDA's list of registered outsourcing facilities.
• The product is described honestly. No claims that it is "the same as Zepbound" or "FDA-approved"; the FDA's 2026 warning letters targeted exactly those claims.
• Price, dose and cancellation terms are published before you pay. Including what happens to the price when your dose goes up and how a multi-month plan can be cancelled.